1. Home
  2. STRS vs CHRS Comparison

STRS vs CHRS Comparison

Compare STRS & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stratus Properties Inc.

STRS

Stratus Properties Inc.

N/A

Current Price

$29.91

Market Cap

244.2M

Sector

Real Estate

ML Signal

N/A

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

N/A

Current Price

$1.67

Market Cap

291.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STRS
CHRS
Founded
1992
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
244.2M
291.5M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
STRS
CHRS
Price
$29.91
$1.67
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
11.9K
1.3M
Earning Date
05-14-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
112.97
472.00
EPS
N/A
1.43
Revenue
$54,183,000.00
N/A
Revenue This Year
N/A
$73.08
Revenue Next Year
N/A
$30.94
P/E Ratio
N/A
$1.16
Revenue Growth
213.74
N/A
52 Week Low
$15.28
$0.72
52 Week High
$32.93
$2.62

Technical Indicators

Market Signals
Indicator
STRS
CHRS
Relative Strength Index (RSI) 52.91 46.37
Support Level $28.22 $1.55
Resistance Level $30.98 $1.75
Average True Range (ATR) 1.11 0.11
MACD -0.14 0.00
Stochastic Oscillator 49.59 26.04

Price Performance

Historical Comparison
STRS
CHRS

About STRS Stratus Properties Inc.

Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the acquisition, entitlement, development, management, operation and sale of commercial, multi- and single-family residential real estate properties, located in the Austin Texas area and other select markets in Texas. It operates its business through two segments namely, Real Estate Operations and Leasing Operations. Real Estate Operations segment encompasses activities associated with entitlement, development, and sale of real estate. Leasing Operations segment involves leasing of commercial space at retail and mixed-use properties and residences in multi-family properties that company developed. Majority of revenue is from Real Estate Operations.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: